Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TRML 
Tourmaline Bio Inc. (TRML)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: TRML (4-star) is a STRONG-BUY. BUY since 71 days. Simulated Profits (153.33%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $48
1 Year Target Price $48
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 257.91% | Avg. Invested days 42 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.23B USD | Price to earnings Ratio - | 1Y Target Price 48 |
Price to earnings Ratio - | 1Y Target Price 48 | ||
Volume (30-day avg) 11 | Beta 1.58 | 52 Weeks Range 11.56 - 48.27 | Updated Date 11/14/2025 |
52 Weeks Range 11.56 - 48.27 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.44 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.85% | Return on Equity (TTM) -29.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 990799869 | Price to Sales(TTM) - |
Enterprise Value 990799869 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -281.95 | Shares Outstanding 25692268 | Shares Floating 13127464 |
Shares Outstanding 25692268 | Shares Floating 13127464 | ||
Percent Insiders 14.62 | Percent Institutions 89.13 |
Upturn AI SWOT
Tourmaline Bio Inc.
Company Overview
History and Background
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines to benefit people with life-altering immune and inflammatory diseases. It was founded in 2021.
Core Business Areas
- Drug Development: Developing novel therapies targeting IL-6 for autoimmune and inflammatory diseases. Their lead product candidate is TOUR006.
Leadership and Structure
Sandeep Markan is the CEO of Tourmaline Bio. The company has a board of directors overseeing strategic direction and management.
Top Products and Market Share
Key Offerings
- TOUR006: TOUR006 is a fully human, high affinity anti-IL-6 antibody being developed for various autoimmune and inflammatory diseases, including Thyroid Eye Disease (TED). There is currently no available market share or revenue data specific to TOUR006. Key competitors in the IL-6 inhibitor space include Roche (Actemra/RoActemra) and Sanofi/Regeneron (Kevzara).
Market Dynamics
Industry Overview
The autoimmune and inflammatory disease market is a large and growing market driven by an aging population, increasing prevalence of autoimmune conditions, and advancements in biotechnology. The IL-6 pathway is a well-validated target for various inflammatory conditions.
Positioning
Tourmaline Bio aims to position itself as a leader in the IL-6 inhibitor space with TOUR006, potentially offering improved efficacy, safety, or convenience compared to existing therapies.
Total Addressable Market (TAM)
The TAM for IL-6 inhibitors in autoimmune and inflammatory diseases is estimated to be in the billions of dollars. Tourmaline Bio's positioning within this TAM depends on the clinical success and market adoption of TOUR006.
Upturn SWOT Analysis
Strengths
- Promising lead product candidate (TOUR006)
- Experienced management team
- Focus on a well-validated target (IL-6)
Weaknesses
- Limited product pipeline
- Reliance on the success of TOUR006
- No products currently generating revenue
Opportunities
- Expansion into additional indications for TOUR006
- Potential for strategic partnerships or acquisitions
- Advancements in drug delivery technologies
Threats
- Competition from established IL-6 inhibitors
- Clinical trial failures
- Regulatory hurdles
- Patent expiry
Competitors and Market Share
Key Competitors
- RHHBY
- SNY
- REGN
Competitive Landscape
Tourmaline Bio aims to compete by demonstrating superior efficacy, safety, or convenience compared to existing IL-6 inhibitors. However, they are currently in clinical development and lack the established market presence of Roche and Sanofi/Regeneron.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by R&D investment and progress through clinical trial phases.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and market launch of TOUR006. Analyst estimates will be available as TOUR006 progresses through development.
Recent Initiatives: Focusing on initiating and completing Phase 2b and Phase 3 trials for TOUR006 in Thyroid Eye Disease (TED).
Summary
Tourmaline Bio is a clinical-stage biotech company with a promising lead candidate, TOUR006, targeting IL-6. Its success hinges on positive clinical trial outcomes and regulatory approval. The company operates in a competitive market dominated by established players. While possessing a focused strategy, it carries inherent risks associated with drug development. A strong financial position and experienced leadership are crucial for its growth trajectory.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Tourmaline Bio Inc. Website
- SEC Filings (10K, 10Q)
- ClinicalTrials.gov
- Analyst Reports (FactSet)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated based on available reports and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tourmaline Bio Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-05-07 | Co-Founder, CEO & Director Dr. Sandeep C. Kulkarni M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 76 | Website https://www.tourmalinebio.com |
Full time employees 76 | Website https://www.tourmalinebio.com | ||
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Tourmaline Bio, Inc. operates as a subsidiary of Novartis AG.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.